Table 3 Risk factors of endocrine disorders in young children with thalassemia major
From: Detection of endocrine disorders in young children with multi-transfused thalassemia major
| Â | Endocrine disorder (28/120) | No endocrine disorder (92/120) | Odds ratio (95% confidence interval) | P value |
|---|---|---|---|---|
Age mean (SD) | 11.60 (3.21) | 11.01 (1.27) | 1.33 (0.48:2.21) | 0.90 |
Gender | ||||
 Females | 12 (42.86%) | 42 (45.65%) | 1 |  |
 Males | 16 (57.14%) | 50 (54.35%) | 1.12 (0.48:2.63) | 0.80 |
Duration of the disease/years Mean (SD) | 6.22 (1.20) | 5.28 (2.64) | 1.20 (0.98:1.45) | 0.07 |
Malnutrition | ||||
 No | 12 (42.86%) | 24 (26.09%) | 1 |  |
 Yes | 16 (57.14) | 68 (73.91) | 0.47 (0.19:1.14) | 0.09 |
Hemoglobin level before blood transfusion (Gram/DL) Mean (SD) | 7.12 (1.62) | 6.69 (1.89) | 1.14 (0.90:1.46) | 0.29 |
Splenectomy | ||||
 No | 13 (46.43%) | 52 (56.52%) | 1 |  |
 Yes | 15 (53.57%) | 40 (43.48%) | 1.50 (0.64:3.50) | 0.35 |
Family history of thalassemia major | ||||
 No | 13 (46.43%) | 33 (35.87%) | 1 |  |
 Yes | 15 (53.57%) | 59 (64.13%) | 0.64 (0.27:1.51) | 0.65 |
Family history of endocrine disorders | ||||
 No | 15 (53.57%) | 58 (63.04%) | 1 |  |
 Yes | 13 (46.43%) | 34 (36.96%) | 1.48 (0.63:3.48) | 0.37 |
Ferritin level Mean (SD) | 3631.45(1636) | 2658.40 (1443) | 0.98 (0.96–0.99) | 0.003 |
Deferasirox | ||||
 No | 16 (57.14%) | 68(73.91%) | 1 |  |
 Yes | 12 (42.86%) | 24 (26.09%) | 2.13 (0.88:5.13) | 0.09 |
Desferoxamine | ||||
 No | 21 (75.00%) | 74 (80.43%) | 1 |  |
 Yes | 7 (25.00%) | 18 (19.57%) | 1.37 (0.50:3.72) | 0.54 |
Combined therapy | ||||
 No | 19 (67.86%] | 42 (45.65%) | 1 |  |
 Yes | 9 (32.14%) | 50 (54.35%) | 0.40 (0.16:0.97) | 0.04 |
Compliance to medication | ||||
 Received ≤50%/month | 19 (67.86%] | 41(44.57% | 1 |  |
 Received > 50/month | 9 (32.14%) | 51 (55.43% | 0.38 (0.16:0.93) | 0.03 |